QL Biopharm’s Zovaglutide Offers Potentially Safer Once-Monthly Obesity Option

Phase III Program Now Planned

 
• By Dexter Jie Yan
  
QL Biopharm believes less frequent dosing may encourage obesity patients to stay longer on treatment (Shutterstock)

More from Clinical Trials

More from R&D